M&A / Deals Biogen swoops on Apellis with $5.6bn offer PharmaphorumIn today's second sizeable M A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology.M&A / DealsNephrologyRead full story pharminent March 31, 2026 (Last updated: March 31, 2026) Pharmaphorum In today’s second sizeable M A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology. M&A / DealsNephrologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly makes $7.8bn takeover play for CentessaNext: Novartis, Takeda Add Hundreds to Workforce Chopping Block Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
